Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study "AFASAK II"


Phase 3 Results

Trial Description

To investigate the effect of minidose warfarin alone and in combination with aspirin in patients with chronic nonvalvular atrial fibrillation.


  • Aspirin (stroke prevention) Drug
    Intervention Desc: Antiplatelet agent; inhibits thromboxane A2
  • Warfarin (Coumadin┬«)Drug
    Other Names: Coumadin
    Intervention Desc: Anticoagulant (Vitamin K antagonist)

Trial Design

Randomized, controlled trial of 677 patients at a single center.

Patient Involvement

Patients were assigned to receive warfarin sodium (1.25 mg/d), warfarin sodium (1.25 mg/d) plus aspirin (300 mg/d), aspirin (300 mg/d), or adjusted-dose warfarin with an INR of 2.0 to 3.0.


Type Measure Time Frame Safety Issue
Primary Stroke or a systemic thromboembolic event.
Secondary Transient ischemic attack, acute myocardial infarction, and death.